Pharmalot Ed Silverman STAT Plus: Gilead wins a key battle with the CDC over patents for its Truvada HIV pill
Insurance Bob Herman Judge invalidates parts of the ACA that mandate health coverage of many preventive services and drugs
Pharmalot Ed Silverman STAT Plus: ViiV will make it easier for generic companies to copy its HIV prevention shot, but it’s not clear when
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Pfizer to merge off-patent business with Mylan; conservatives try to sabotage Trump pricing plan
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Glaxo is set to hire a new chairman; Gilead tries to bulk up with new deal
Pharmalot Ed Silverman STAT Plus: AIDS groups criticize Express Scripts for excluding several HIV medicines
Pharmalot Ed Silverman STAT Plus: Gilead will donate Truvada for HIV prevention, but reaction is mixed
Pharmalot Ed Silverman STAT Plus: Once-a-day pills for combating HIV are a better deal than some people think
Health Helen Branswell Patient Zero in AIDS crisis was misidentified, study says, rewriting early history of virus
In the Lab Shayla Love Genetic fossil-hunters dig through HIV’s long history for clues to new treatments
In the Lab Andrew Joseph A drug used to treat Crohn’s disease could suppress HIV, monkey study suggests
Heavyweights Rebecca Robbins The drug pricing crusader at the center of one of the nastiest fights of the election season
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Glaxo believes its plan for HIV treatment is a ‘game changer’
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Another analysis finds new cholesterol drugs are not cost-effective
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Gilead’s preventive HIV pill must be covered in England
First Opinion Peter Piot and Mitchell Warren Prevention must be at the forefront to meet global HIV goals